Toxicodynamic therapeutic drug monitoring of immunosuppressants: Promises, reality, and challenges

Therapeutic Drug Monitoring

Volumn 30, Issue 2, 2008, Pages 151-158

  Christians, Uwe ^a,b   Schmitz, Volker ^c   Schöning, Wenzel ^b,c   Bendrick Peart, Jamie ^a,b   Klawitter, Jelena ^b   Haschke, Manuel ^d   Klawitter, Jost ^a,b  

^a Eurofins Medinet Inc   (Germany)

^b UNIVERSITY OF COLORADO   (United States)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Combinatorial biomarkers; Immunosuppressants; Metabolomics; Nephrotoxicity; Proteomics; Therapeutic drug monitoring; Toxicodynamics; Transcriptomics

Indexed keywords

BIOLOGICAL MARKER; CALCINEURIN INHIBITOR; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN; TACROLIMUS;

ALGORITHM; CELL METABOLISM; CLINICAL TRIAL; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DRUG MONITORING; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY METABOLISM; KIDNEY TRANSPLANTATION; KIDNEY TUBULE; KIDNEY TUBULE ABSORPTION; METABOLOMICS; NONHUMAN; ORGAN TRANSPLANTATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEOMICS; TRANSCRIPTOMICS; URINALYSIS;

ANIMALS; BIOLOGICAL MARKERS; CALCINEURIN; CYCLOSPORINE; DRUG INTERACTIONS; DRUG MONITORING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEOMICS; RATS; SIROLIMUS;

EID: 42049112365     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31816b9063     Document Type: Conference Paper

References (33)

1. Biomarkers Definition Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89-95.
2. Koop R. Combinatorial biomarkers: from early toxicology assays to patient population profiling. Drug Discov Today. 2005;10:781-788.
3. Ilyin SE, Belkowski SM, Plata-Salamán CR. Biomarker discovery and validation: technologies and integrative approaches. Trends Biotechnol. 2004;22:411-416.
4. Baluja P, Haragsim L, Laszik Z. Chronic allograft dysfunction. Adv Chronic Kidney Dis. 2006;13:55-61.
5. Berl T. American Society of Nephrology Renal Research Report. J Am Soc Nephrol. 2005;16:1886-1903.
6. Hariharan S, Johnson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med. 2000;342:605-612.
7. Meier-Kriesche HU, Schold JD, Srinivas TR, et al. Lack of improvement in allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant. 2004;4:378-383.
8. Kaplan B. Overcoming barriers to long-term graft survival. Am J Kidney Dis. 2006; 47(4 Suppl 2):S52-S64.
9. Kreis H. Management of the transplant recipient. In: Davision AM, Cameron JS, Grunfeld J-P, et al, eds. Oxford Textbook of Clinical Nephrology, ed 2. Oxford: Oxford University Press, 1998:2153-2176.
10. Chapman JR, O'Connell PJ, Nankivell BJ. Chronic renal allograft dysfunction. J Am Soc Nephrol. 2005;16:3015-3026.
11. Campistol JM, Grinyo JM. Exploring treatment options in renal transplantation: the problems of chronic allograft dysfunction and drug-related nephrotoxicity. Transplantation. 2001;71(Suppl 11)SS42-SS51.
12. Kee TY, Chapman JR, O'Connell PJ, et al. Treatment of subclinical rejection diagnosed by protocol biopsy of kidney transplants. Transplantation. 2006;82:36-42.
13. Merville P. Combating chronic renal allograft dysfunction. Optimal immunosuppressive regimens. Drugs. 2005;65:615-631.
14. Miyagi M, Ishikawa Y, Mizuiri S, et al. Significance of subclinical rejection in early renal allograft biopsies for chronic allograft dysfunction. Clin Transplant. 2005;19:456-465.
15. Christians U, Reisdorph N, Klawitter J, et al. Biomarkers of immunosuppressive drug toxicity. Curr Opin Organ Transplant. 2005;10:284-294.
16. Raulf F. Novel biomarkers of allograft rejection: 'omics' approaches start to deliver. Curr Opin Organ Transplant. 2005;10:295-300.
17. Clarke W. Proteomic research in renal transplantation. Ther Drug Monit. 2006;28:19-22.
18. Schaub S, Mayr M, Hönger G, et al. Detection of subclinical tubular injury after renal transplantation: comparison of urine protein analysis with allograft histopathology. Transplantation. 2007;84:104-112.
19. Anderson NL, Polanski M, Pieper R, et al. The human plasma proteome: a nonredundant list developed by combination of four separate sources. Mol Cell Proteomics. 2004;3:311-326.
20. Nicholson JK, Lindon JC, Holmes E. "Metabolomics": understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica. 1999;29:1181-1189.
21. Griffin JL. Metabolomics: NMR spectroscopy and pattern recognition analysis of body fluids and tissues for characterization of xenobiotics toxicity and disease diagnostic. Curr Opin Chem Biol. 2003;7:648-654.
22. Pelczer I. High-resolution NMR for metabolomics. Curr Opin Drug Discov Dev. 2005;8:127-133.
23. Dunn WB, Bailey NJ, Johnson SE. Measuring the metabolome: current analytical technologies. Analyst. 2005;130:606-625.
24. Nicholson JK, Connelly J, Lindon JC, et al. Metabolomics: a platform for studying drug toxicity and gene function. Nat Rev Drug Discov. 2002;1:153-161.
25. Shockcor JP, Holmes E. Metabolomic applications in toxicity screening and disease diagnosis. Curr Top Med Chem. 2002;2:35-51.
26. Flechner SM, Kurian SM, Head SR, et al. Kidney transplant rejection and tissue injury by gene profiling of biopsies and peripheral blood lymphocytes. Am J Transplant. 2004;4:1475-1489.
27. Einecke G, Broderick G, Sis B, et al. Early loss of renal transcripts in kidney allografts: relationship to the development of histologic lesions and alloimmune effector mechanisms. Am J Transplant. 2007;7:1121-1130.
28. Halloran PF, Einecke G. Microarrays and transcriptome analysis in renal transplantation. Nat Clin Pract Nephrol. 2006;2:2-3.
29. 2t-isoprostane in human urine and plasma using high-performance liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry. Clin Chem. 2007;53:489-497.
30. Lorenz JN, Gruenstein E. A simple, nonradioactive method for evaluating single-nephron filtration rate using FITC-inulin. Am J Physiol. 1999;276:F172-F177.
31. Racusen LC, Solez K. Cyclosporine nephrotoxicity. Int Rev Exp Pathol. 1988;30:107-157.
32. Andoh TF, Burdmann EA, Lindsley J, et al. Enhancement of FK506 nephrotoxicity by sodium depletion in an experimental rat model. Transplantation. 1994;57:483-489.
33. Christians U, Gottschalk S, Miljus J, et al. Alterations in glucose metabolism by cyclosporine in rat brain slices link to oxidative stress: interactions with mTOR inhibitors. Br J Pharmacol. 2004;143:388-396.